onc brain

The longer read

The useful contribution here is not that post-prostatectomy radiotherapy costs continence, which the clinician-rated RAVES, GETUG-AFU 17 and RADICALS toxicity data already established, but the decomposition of where the salvage strategy's functional advantage actually comes from. Two comparisons in this analysis point in opposite directions and the reconciliation is the whole argument. Against men who never needed radiotherapy at all, adjuvant treatment looks clearly worse: more bowel symptom deterioration at every timepoint, and severe urinary leakage of 16% versus 2% at five years. Against men who did require salvage and got it, adjuvant treatment looks equivalent: 16% versus 13% severe leakage, p = 0.7, and no regression coefficient linking the surgery-to-radiotherapy interval to any domain at three, four, or five years. So the salvage approach buys quality of life by sparing roughly half the arm from radiotherapy entirely, not by putting distance between surgery and treatment. That distinction matters clinically because it removes any functional argument for temporizing once salvage is indicated, which is exactly the direction early-salvage biochemical thresholds have been pushing.

How much confidence the toxicity magnitude deserves is a separate question, and the answer differs by domain. The urinary finding is the more durable of the two: a fourfold to eightfold difference in severe leakage is large, it is consistent across the fourth and fifth years, and it sits inside the 10 to 20% band that clinician-rated incontinence series have reported, so two independent measurement approaches converge. The bowel finding is softer than its headline suggests. A minimal clinically important change of 0.5 SD translated to two points on a hundred-point scale for the bowel domain, while the instrument's own granularity means the smallest change a man can register is 8.3 points. The threshold is therefore not doing any discriminating work, and the reported proportions are counting anyone who moved a single Likert step on one of four questions. The authors say as much. That the same signal is absent from clinician-rated gastrointestinal toxicity is consistent with a real but minor effect rather than a null one, but it should not be read as equivalent in weight to the continence result.

The comparison that carries the most striking numbers is also the one that is not randomized. Men in the salvage arm who never received radiotherapy are defined by not having recurred, which selects on disease biology and plausibly on baseline function as well. Any residual imbalance in comorbidity, medication, or post-prostatectomy continence flows straight into that 16% versus 2% contrast, and comorbidities were not analyzed. The randomized comparison, adjuvant versus the salvage arm as allocated, is more conservative and shows differences that resolve by three years except for bowel symptoms.

The generalization problem is technique vintage. Most men were treated with 3D-CRT to 64 Gy in 32 fractions, fossa only, with no androgen deprivation and no nodal coverage. Contemporary practice is IMRT, increasingly hypofractionated, and after SPPORT increasingly with short-course androgen deprivation and pelvic nodes in higher-risk men. The rectal dose reduction with IMRT argues the bowel signal here overstates what a modern patient would report. Nodal coverage and androgen deprivation argue the opposite for everything else. A reader should treat these numbers as a floor for the continence cost and a probable ceiling for the bowel cost, and should not extend either to hypofractionated regimens until NRG-GU003 and the salvage SBRT series report their long-term patient-reported outcomes.